证券代码：002551 证券简称：尚荣医疗 公告编号：2025-038 深圳市尚荣医疗股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 深圳市尚荣医疗股份有限公司（以下简称"公司"或"本公司"）（股票简 称：尚荣医疗，股票代码：002551）股票交易价格连续2个交易日内（2025年8 月7日和2025年8月8日）收盘价格涨幅偏离值累计达到20%，根据《深圳证券交易 所交易规则》等有关规定，属于股票交易异常波动的情形。 二、公司关注及核实情况说明 针对公司股票交易异常波动情况，公司董事会通过电话及现场问询等方式， 对公司控股股东、实际控制人、公司董事、监事及高级管理人员就相关问题进行 了核实，现将有关情况说明如下： 1、截止本公告日，公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共媒体报道了可能或者已经对公司股票交易价格产生 较大影响的公司未公开的重大信息。 3、近期公司经营情况正常，内外部经营环境未发生重大变化或预计将要发 生重大变化的情形。 4、经查询，公司及控股股东、实际控制人 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth in the A-share market, with the BCI index reaching a historical high, indicating a promising future for the industry [2][3]. Industry Overview - The BCI technology is seen as a new frontier, with applications in medical fields such as disease warning, diagnosis, treatment, and functional enhancement, as well as in non-medical sectors like consumer and industrial applications [5][6]. - The global market for BCI medical applications is projected to reach $40 billion by 2030 and $145 billion by 2040, highlighting the substantial growth potential in this sector [5]. Company Developments - Several companies, including Sainuo Medical, Guangdian Co., and Shangrong Medical, have seen their stock prices surge, with multiple stocks hitting the daily limit up [3]. - Companies like Lide Man and Botuo Bio have reported significant gains, with Lide Man increasing over 11% and Botuo Bio rising by 10% [3]. - Sanbo Brain Science has completed an interventional BCI trial, showcasing China's innovation capabilities in this field and marking a significant step in treating movement disorders [3]. Strategic Initiatives - Chengyitong has established a dual-track strategy focusing on both invasive and non-invasive BCI technologies, aiming to integrate existing rehabilitation devices with BCI [4]. - Yanshan Technology's subsidiary has developed a brain-computer interface system that has demonstrated excellent performance in clinical trials, indicating advancements in the technology [5]. Policy Support - The Chinese government has been actively promoting the BCI industry through various policies, with multiple regions releasing action plans to accelerate development [6]. - The Ministry of Industry and Information Technology has outlined goals for the BCI sector over the next five years, aiming for breakthroughs in key technologies and the establishment of a robust industrial ecosystem by 2030 [6][7]. Market Challenges and Opportunities - The BCI industry faces challenges in making technology affordable for the general public, with current rehabilitation robots costing around 1 million yuan, which is still considered expensive [7][8]. - The integration of BCI technologies into medical insurance reimbursement lists is seen as a critical step for commercial viability and wider adoption [8].

Core Viewpoint - The brain-computer interface (BCI) industry is expected to experience significant growth, with 2023 being a pivotal year for its development and application across various sectors [2][8]. Group 1: Market Performance - The BCI concept stocks have seen a strong rally, with several companies like Sainuo Medical, Guangdian Co., and Shangrong Medical hitting their daily price limits [4]. - Notable stock performances include Lide Man and Botuo Bio, which rose over 11%, and Meilan De, which increased by 10% [4]. Group 2: Technological Advancements - BCI technology connects the brain with external devices for information exchange, showing promise in medical fields such as disease diagnosis and treatment [6]. - Significant advancements have been made in BCI technology, particularly in biomedical applications, neuro-rehabilitation, and intelligent robotics [6]. Group 3: Industry Outlook - According to McKinsey, the global market for BCI medical applications is projected to reach $40 billion by 2030 and $145 billion by 2040 [7]. - The Chinese BCI industry, although starting late, is rapidly developing, with multiple policies introduced since 2025 to support its growth [9][10]. Group 4: Policy Support - Recent government initiatives aim to accelerate the commercialization of BCI technology, with specific action plans released by cities like Beijing and Shanghai [9][10]. - The Ministry of Industry and Information Technology and other departments have set ambitious goals for the BCI industry over the next five years, focusing on technological breakthroughs and establishing a robust industrial ecosystem [10]. Group 5: Application Areas - The BCI industry has two primary application areas: serious medical applications, such as rehabilitation for stroke and spinal injury patients, and consumer applications addressing issues like sleep disorders [11]. - A significant challenge for the industry is to reduce costs, making BCI technologies more accessible to the general public [11][12].

来源：金融界 主力资金净流出居前的分别为安必平（1174.99万元）、东富龙（1070.65万元）、安杰思（995.13万 元）、微电生理（983.9万元）、可孚医疗（916.41万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.71-0.031.07亿元7.18%2300003 乐普医疗17.276.931.07亿元5.73%3301363美好医疗20.037.175599.57万元11.04%4603987康德莱 9.235.734851.48万元12.43%5870199倍益康42.581.383949.32万元7.52%6002551尚荣医疗4.649.953736.73 万元22.93%7688068热景生物243.022.543614.97万元6.9%8688314康拓医疗40.08.113278.73万元 15.1%9688108赛诺医疗20.4420.022762.62万元19.98%10832278鹿得医疗12.484.962727.93万元13.05% 8月8日，医疗器械行业上涨0.93%，今日主力资金流出6.11亿元，成分股59只上涨，39只下跌。 ...

Market Overview - A-shares experienced narrow fluctuations in the morning session, with the three major indices showing slight increases. The total trading volume in the Shanghai and Shenzhen markets was 1.08 trillion, a decrease of 111.9 billion compared to the previous trading day [1] - The market sentiment was mixed, with over 2900 stocks declining, indicating a broader trend of weakness among individual stocks [1] Sector Performance - The super hydropower concept stocks rebounded, with Shanhe Intelligent hitting the daily limit [3] - The commercial aerospace sector saw a brief surge, with Shanghai Huguang also reaching the daily limit [3] - Medical device stocks remained active, with Shangrong Medical hitting the daily limit [3] - In contrast, AI application stocks collectively adjusted, with Jinxiandai dropping over 10% [3] - Sectors that performed well included super hydropower, brain-computer interface, medical devices, and steel, while sectors that saw declines included multimodal AI, Huawei Ascend, semiconductors, and education [3] - By the end of the session, the Shanghai Composite Index rose by 0.07%, the Shenzhen Component Index increased by 0.14%, and the ChiNext Index gained 0.21% [3]

医疗器械 ETF（562600）为投资者提供一键把握医疗器械行业成长机遇的便捷工具。该ETF追踪的中证 全指医疗器械指数，精心选取 100 支覆盖医疗器械、医疗服务、医疗信息化等核心医疗领域的代表性上 市公司证券作为样本。按wind脑机接口指数测算，截至2025年8月6日指数含脑机接口权重21.9%，从行 业结构看，该指数医疗器械行业占比高达 89.08%，集中度突出，能精准捕捉医疗器械领域的发展红 利。感兴趣的投资者可以持续关注。 （文章来源：每日经济新闻） 提出到2027年、2030年两步走发展目标，明确五大重点任务，细化17项具体举措，进一步推动脑机接口 产业高质量发展。这一重磅文件的出台，为我国脑机接口产业的未来发展描绘了清晰的蓝图，有望在全 球科技竞争中抢占先机，培育出具有国际竞争力的未来产业新赛道。 受此影响，医疗器械板块持续活跃，医疗器械ETF短暂调整后直线拉升，发稿时涨超1%。持仓股票赛 诺医疗20厘米涨停，利德曼、麦澜德、尚荣医疗、美好医疗涨幅居前。 消息面，工业和信息化部、国家发展改革委等7 部门发布关于推动脑机接口产业创新发展的实施意见。 ...

经济观察网 医疗器械板块短线拉升，尚荣医疗、赛诺医疗涨停, 爱朋医疗、翔宇医疗涨超10%，伟思医 疗、中红医疗、济高发展、冠昊生物、港通医疗等跟涨。 ...

Group 1 - The core point of the article is that Shangrong Medical (002551) experienced a significant increase in stock price, closing at 4.22 yuan with a 9.9% rise and hitting the daily limit [1] - On August 7, 2025, the stock reached its limit at 9:40 AM and did not open again, with a closing order amounting to 57.46 million yuan, representing 2.23% of its circulating market value [1] - The net inflow of main funds on that day was 73.99 million yuan, while retail funds saw a net outflow of 42.47 million yuan [1] Group 2 - The trading volume for Shangrong Medical on August 7 was 341,200 hands, with a total transaction amount of 141 million yuan [1] - The turnover rate for the stock was recorded at 5.58% [1] - The net outflow of speculative funds was 31.52 million yuan [1]

Core Viewpoint - The medical device sector is experiencing a significant upward trend, with multiple stocks reaching their daily limits, indicating strong investor interest and potential growth opportunities in the industry [1]. Group 1: Stock Performance - Medical device concept stocks are showing volatility with notable gains, including Shangrong Medical and Kehua Bio, both hitting the daily limit [1]. - Sino Medical also reached the daily limit during bidding, while Lideman and Zhonghong Medical increased by over 10% [1]. - Other companies such as Yangpu Medical, Nanwei Shares, BGI Genomics, and Kaili Medical saw increases of over 5% [1]. Group 2: Investment Opportunities - According to a report from CITIC Securities, future investment opportunities in the medical device sector are increasingly linked to internationalization [1]. - Several companies are expected to achieve high growth in their international business by 2025, with a continuous increase in the proportion of revenue from international operations [1]. - Companies with significant long-term potential in international business are likely to experience a revaluation of their stock prices [1].

截至3月31日，尚荣医疗股东户数5.83万，人均流通股1.05万股。 2025年1月-3月，尚荣医疗实现营业收入2.8亿元，同比增长1.30%；归属净利润1396.42万元，同比增长 0.58%。 8月7日，尚荣医疗盘中9.9%涨停，截至09:40，报4.22元/股，成交5229.83万元，换手率2.15%，总市值 35.68亿元。 资料显示，深圳市尚荣医疗股份有限公司位于深圳市龙岗区宝龙工业城宝龙五路2号尚荣科技工业园1号 厂房2楼，公司主要业务是提供现代化医院建设整体解决方案，包括医疗产品、医疗服务和产业整合三 大业务板块。公司通过并购投资，构建起覆盖医院规划设计、医院建设、医疗专业工程、医用软件开 发、医疗设备销售、医用耗材销售、医院后勤托管、医院建设及投资全产业链条，使公司在市场竞争中 处于领先地位。 来源：金融界 ...